Analysts Conflicted on These Healthcare Names: Pliant Therapeutics (PLRX) and Capricor Therapeutics (CAPR)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Pliant Therapeutics (PLRX – Research Report) and Capricor ...
Pliant Therapeutics stock tumbles amid IPF trial cancellation
The company’s stock price has dropped to around $1.38 per share after its IPF therapy trial was stopped for safety.
Needham downgrades Pliant Therapeutics (PLRX) to a Hold
Pliant Therapeutics (PLRX – Research Report) received a Hold rating and price target from Needham analyst Joseph Stringer today. The ...
Neumora bids farewell to R&D head; Biohaven’s ‘one step forward, one step back’ data
Robert Lenz is leaving the brain drug developer to “pursue other interests.” Elsewhere, Acelyrin rejected a bid by Concentra ...
TipRanks on MSN13h
Pliant Therapeutics Reports Q4 2024 Results and Updates
Pliant Therapeutics, Inc. ( ($PLRX) ) has released its Q4 earnings. Here is a breakdown of the information Pliant Therapeutics, Inc. presented to ...
Investing18h
Pliant Therapeutics shares rise on better-than-expected Q4 earnings
SOUTH SAN FRANCISCO - Pliant Therapeutics, Inc. (NASDAQ: PLRX) reported fourth quarter earnings that beat analyst estimates, sending shares up 6.5% in after-hours trading. The clinical-stage ...
Santé log19h
Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis
Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following a prespecified data review and recommendation by the trial’s independent Data Safety Monitoring Board (DSMB), as well as a ...
Pliant Therapeutics Stock Sinks, Discontinues Mid-Stage Study For Lung Disorder
Pliant Therapeutics discontinued its BEACON-IPF trial for bexotegrast due to safety concerns but observed early efficacy. The ...